| J9271 | Injection, pembrolizumab, 1 mg | 18,800 | $40 | $808.4K |
| J0897 | Injection, denosumab, 1 mg | 7,860 | $20 | $141.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 610 | $100 | $61.1K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 3,300 | $20 | $52.8K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 470 | $90 | $40.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 550 | $70 | $39.7K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 270 | $110 | $30.6K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13,080 | $1 | $26.2K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 60 | $180 | $11K |
| 99222 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 100 | $110 | $10.3K |